Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XP23829 · 1 trial · 1 indication
The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The minimum possible score on this scale is '0', while the maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of subject.
| Arm | Type | Description |
|---|---|---|
| XP23829 400 mg QD (once daily) | EXPERIMENTAL | After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period |
| XP23829 800 mg QD | EXPERIMENTAL | After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period |
| XP23829 400 mg BID (twice daily) | EXPERIMENTAL | After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period |
| Placebo | PLACEBO_COMPARATOR | After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks |
| Name | Type | Description |
|---|---|---|
| XP23829 400 mg QD | DRUG | active dose 1 |
| XP 23829 800 mg QD | DRUG | active dose 2 |
| XP23829 400 mg BID | DRUG | active dose 3 |
| Placebo | DRUG | control |
Inclusion Criteria: 1. Male and female subjects, age ≥ 18. 2. Stable, moderate-to-severe plaque-type psoriasis diagnosed for at least 6 months prior to randomization (no morphology changes or significant flares of disease activity in the last 6 months in the opinion of the investigator). 3. Severit...
XP23829 is an investigational small molecule being studied for the treatment of moderate-to-severe chronic plaque-type psoriasis. It is a dermatology asset in Phase 2 clinical development, evaluated in a randomized, double-blind, placebo-controlled trial in the United States.
XP23829 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting clinical research on this small molecule for psoriasis.
XP23829 is in Phase 2 clinical development. It is an investigational drug, not yet approved, and has completed one Phase 2 trial. The study assessed its efficacy and safety in patients with moderate-to-severe chronic plaque-type psoriasis.
XP23829 has one completed clinical trial, identified as NCT02173301, titled 'A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis'. This Phase 2 study enrolled 200 participants in the United States and was randomized, double-blind, and placebo-controlled.
XP23829 is not FDA approved. It is an investigational small molecule currently in Phase 2 clinical development for psoriasis. The drug has completed a Phase 2 trial, but it remains under study and has not received regulatory approval.